Last reviewed · How we verify
ABT-267
ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation.
ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation. Used for Diabetic kidney disease, Liver fibrosis / NASH (non-alcoholic steatohepatitis).
At a glance
| Generic name | ABT-267 |
|---|---|
| Also known as | ombitasvir, Ombitasvir, ABT-267 also known as ombitasvir |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | CCR2 antagonist |
| Target | CCR2 (C-C chemokine receptor type 2) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
ABT-267 blocks CCR2, a G-protein coupled receptor expressed on monocytes and other immune cells, thereby decreasing their migration to inflamed tissues. This mechanism is intended to reduce inflammatory responses in diseases characterized by excessive monocyte infiltration and activation. The drug was developed to address inflammatory and fibrotic conditions where monocyte-driven inflammation plays a pathogenic role.
Approved indications
- Diabetic kidney disease
- Liver fibrosis / NASH (non-alcoholic steatohepatitis)
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Headache
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
- Study of Oral Treatments for Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-267 CI brief — competitive landscape report
- ABT-267 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI